These mutations in APC lead to unrestricted activation of β-catenin, which in turn activates many genes responsible for tumorigenesis, such as MYC. In fact, an integrated genetic analysis by The Cancer Genome Atlas (TCGA) Network showed that nearly 100% of CRC tumors showed changes in transcriptional targets of MYC [13]. The gene discussed is MYC; the disease is colorectal carcinoma.